logo
J&J Snack Foods (JJSF) Reports Earnings Tomorrow: What To Expect

J&J Snack Foods (JJSF) Reports Earnings Tomorrow: What To Expect

Yahoo2 days ago
Snack food company J&J Snack Foods (NASDAQ:JJSF) will be reporting earnings this Tuesday morning. Here's what investors should know.
J&J Snack Foods missed analysts' revenue expectations by 3.2% last quarter, reporting revenues of $356.1 million, down 1% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' adjusted operating income estimates and a significant miss of analysts' EBITDA estimates.
Is J&J Snack Foods a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting J&J Snack Foods's revenue to grow 1.2% year on year to $445.3 million, slowing from the 3.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.76 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. J&J Snack Foods has missed Wall Street's revenue estimates five times over the last two years.
Looking at J&J Snack Foods's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hershey delivered year-on-year revenue growth of 26%, beating analysts' expectations by 3.1%, and Lamb Weston reported revenues up 4%, topping estimates by 5.7%. Hershey's stock price was unchanged after the resultswhile Lamb Weston was up 19.3%.
Read our full analysis of Hershey's results here and Lamb Weston's results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the shelf-stable food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.4% on average over the last month. J&J Snack Foods is down 3.6% during the same time and is heading into earnings with an average analyst price target of $144 (compared to the current share price of $112.21).
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
登入存取你的投資組合
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

S&P/TSX composite starts the week on the rise while U.S. markets fall
S&P/TSX composite starts the week on the rise while U.S. markets fall

Yahoo

time2 minutes ago

  • Yahoo

S&P/TSX composite starts the week on the rise while U.S. markets fall

TORONTO — Canada's main stock index jumped two per cent Tuesday as it caught up to a Monday market rally, while U.S. markets were down. The S&P/TSX composite index rose 549.65 points to 27,570.08 in broad gains after being closed Monday for the August long weekend. In New York, the Dow Jones industrial average was down 61.90 points to 44,111.74. The S&P 500 index was down 30.75 points at 6,299.19, while the Nasdaq composite was down 137.03 points at 20,916.55. The Canadian dollar traded for 72.54 cents US compared with 72.48 cents US on Friday. The September crude oil contract was down US$1.13 at US$65.16 per barrel. The December gold contract was up US$8.30 at US$3,434.70 an ounce. This report by The Canadian Press was first published Aug. 5, 2025. The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time2 minutes ago

  • Yahoo

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@

Bio-Techne Announces Exosome Diagnostics Divestiture
Bio-Techne Announces Exosome Diagnostics Divestiture

Yahoo

time2 minutes ago

  • Yahoo

Bio-Techne Announces Exosome Diagnostics Divestiture

MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar. "Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market." Kelderman continued, "Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector leading operating margin profile." "ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business," said Michael McGarrity, Chief Executive Officer of Mdxhealth. "The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool. We are looking forward to building on this success." Under the terms of the agreement, Bio-Techne will receive $5 million in MDXH stock combined with future considerations. The transaction is expected to be completed during the first quarter of Bio-Techne's fiscal 2026. Bio-Techne will discuss this transaction, as well as its fourth quarter fiscal 2025 performance on its earnings call tomorrow, August 6th, 2025, at 8:00 a.m. CDT. To listen, please dial 1-800-274-8461 or 1-203-518-9814 (for international callers), and reference conference ID: TECHQ4. The earnings call can also be accessed via webcast through the following link Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding our belief about the impact of our pending divestiture of Exosome Diagnostics Inc. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About mdxhealth®Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California, with additional laboratory operations in Plano, Texas. For more information, visit and follow us on social media at: and For more information:info@ LifeSci Advisors (IR & PR)John FrauncesManaging DirectorTel: +1 917 355 2395Jfraunces@ ir@ View original content to download multimedia: SOURCE Bio-Techne Corporation

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store